
Yüksel Ürün/X
Aug 4, 2025, 20:01
Yüksel Ürün: How Should We Treat mCRPC and HRR Deficiency?
Yüksel Ürün, Medical Oncology professor at Ankara University School of Medicine, shared a post on X:
“How should we treat? Patients with metastatic castration-resistant prostate cancer (mCRPC) and HRR deficiency who have already received an ARPI for metastatic castration-sensitive prostate cancer (mCSPC).
- PARPi monotherapy
- PARPi plus ARPI
- Other.”
More posts featuring Yüksel Ürün on Oncodaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 4, 2025, 20:01
Aug 4, 2025, 18:55
Aug 4, 2025, 18:34
Aug 4, 2025, 18:11
Aug 4, 2025, 18:08
Aug 4, 2025, 18:02